Tenaya Therapeutics Says FDA Clears IND Application And Initiation Of Phase 1 For TN-301
(RTTNews) - Biotechnology company Tenaya Therapeutics, Inc. (TNYA) announced Tuesday the clearance of its Investigational New Drug (IND) application to begin clinical testing of TN-301 by the U.S. Food and Drug Administration (FDA).
TN-301 is Tenaya's highly selective small molecule inhibitor of histone deacetylase 6 (HDAC6), initially being developed for the potential treatment of heart failure with preserved ejection fraction (HFpEF). Tenaya has initiated its first-in-human Phase 1 clinical trial of TN-301 in healthy adult participants.
Tenaya's Phase 1 randomized, double-blind, placebo-controlled clinical study is designed to evaluate the safety and tolerability of escalating oral doses of TN-301. Secondary objectives of the study will be to assess pharmacokinetics and pharmacodynamics (PD) measures.
The Phase 1 trial will enroll healthy adult participants in two stages. In Stage 1, participants will receive single ascending doses (SAD) of either TN-301 or placebo.
Based on emerging data from the SAD portion of the study, including PD evidence of target engagement, participants in Stage 2 will receive multiple ascending doses of TN-301 at dose levels of interest to help guide dosing in future studies.
For More Such Health News, visit rttnews.com
TSX Continues To Climb Higher, Extends Winning Streak To 9th Straight Day
Dollar Loses Ground Against Major Counterparts
Swiss Market Ends Marginally Up
European Stocks Fail To Hold Early Gains, Close Flat
Pound Higher After Strong U.K. PMI Data
U.S. Consumer Sentiment Deteriorates More Than Previously Estimated In January
Eurozone Private Sector Grows In January
